Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for diseases with high unmet medical need. Its pipeline is centered on endocrine disorders and neurodegenerative diseases, with avexitide as the lead asset and additional programs including AMX0035, AMX0114, and AMX0318. The company previously commercialized RELYVRIO/ALBRIOZA for ALS in the U.S. and Canada, but that product was voluntarily withdrawn from the market in 2024. Today, Amylyx is primarily a research-and-development organization that is trying to convert its pipeline into future commercial products, while relying heavily on third-party manufacturers and potential partners for development and commercialization.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDevelopment of avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism.
Pipeline programs including AMX0035 and AMX0114 aimed at neurodegenerative and rare neurologic diseases.
Programs such as AMX0318 and related work targeting PBH and other rare endocrine conditions.
RELYVRIO/ALBRIOZA, the former ALS product that was voluntarily withdrawn from the market.
Clinical operations, regulatory support, and outsourced manufacturing oversight needed to advance the pipeline.
Customers
Amylyx does not currently have a broad commercial customer base because it is primarily a clinical-stage company. Its near-term end users are patients with rare endocrine and neurodegenerative diseases, while the actual purchasing and reimbursement decisions would be made by hospitals, specialty pharmacies, physicians, and payors if products are approved. The company’s prior commercial experience came from RELYVRIO/ALBRIOZA sales in the U.S. and Canada, which were directed at ALS patients and their care teams before withdrawal. Future commercialization would likely depend on orphan-disease specialists, neurology centers, endocrinology centers, and third-party collaborators that can help market and distribute approved therapies.
Patients with post-bariatric hypoglycemia or congenital hyperinsulinism who would use avexitide or related therapies if approved.
Patients with ALS, Wolfram syndrome, PSP, and related conditions targeted by AMX0035 and AMX0114.
Neurology and endocrinology specialists who diagnose, prescribe, and monitor rare-disease therapies.
Insurers and health systems that determine access and coverage for high-cost orphan drugs.
Partners that may provide sales, marketing, pharmacovigilance, and distribution capabilities for approved products.
Strategy
Amylyx’s strategy is to build value from a focused pipeline in rare endocrine and neurodegenerative diseases rather than from a broad commercial franchise. The company is prioritizing avexitide, which has received FDA breakthrough and orphan-related designations, because regulatory differentiation can improve the odds of approval in a small but medically important market. It is also advancing AMX0035, AMX0114, and AMX0318 to diversify its pipeline and reduce dependence on any single asset. Because the company has limited internal commercialization infrastructure, it is also positioning itself to use collaborations or other strategic transactions to support future launches and market access.
Avexitide is the lead asset and the most advanced opportunity to create future commercial revenue.
Multiple programs reduce dependence on a single indication and improve long-term optionality.
The company lacks a durable internal sales and distribution engine after the RELYVRIO withdrawal.
Clinical-stage development requires sustained funding before any product revenue returns.
Geography
Amylyx is headquartered in the United States and its historical commercial activity was concentrated in the U.S. and Canada through RELYVRIO/ALBRIOZA. The company’s current pipeline is global in the sense that it depends on U.S. FDA and other regulatory pathways, foreign patent protection, and international clinical and manufacturing capabilities. Its supply chain is geographically dispersed because it relies on third-party contract manufacturers and API suppliers, which creates exposure to cross-border logistics, tariffs, and geopolitical disruptions. The company also maintains a broad foreign patent estate, indicating that future value creation may depend on protection and eventual commercialization outside the U.S.
Risks
Amylyx faces the core risk profile of a clinical-stage biotech: most of its value depends on successful clinical development, regulatory approval, and eventual commercialization of a small number of assets. The company has already lost its prior commercial product, so it currently has no ongoing product revenue and expects losses to continue until a new product is approved and adopted. Its reliance on third-party manufacturers and single-source APIs creates supply, quality, and timing risk, especially for peptide-based therapies where capacity can be constrained by broader industry demand. In addition, the markets for rare diseases such as PBH, congenital HI, Wolfram syndrome, and ALS may be smaller than expected, and even approved products may face reimbursement, physician adoption, and competition from better-funded rivals.
- Pipeline development and regulatory failureImpact: CriticalLikelihood: High
The company’s value depends on a small number of investigational therapies reaching approval and showing meaningful benefit.
Exposure - Loss of commercial revenue after RELYVRIO/ALBRIOZA withdrawalImpact: HighLikelihood: High
The company no longer generates product sales from its former ALS franchise, increasing dependence on future approvals and financing.
Exposure: U.S. and Canada commercial operations
- Capital raising riskImpact: HighLikelihood: High
Clinical-stage operations consume cash before product revenue is established, so the company may need dilutive financing or strategic transactions.
Exposure - Manufacturing and supply chain dependenceImpact: HighLikelihood: Medium
Amylyx relies on third-party CMOs and single manufacturers for APIs and drug product, which can cause delays, shortages, or cost inflation.
Exposure - Market size and reimbursement riskImpact: MediumLikelihood: High
Rare-disease markets may be smaller than expected and payor acceptance may limit uptake even after approval.
Exposure - Intellectual property protectionImpact: MediumLikelihood: Low
Patent coverage is central to protecting future exclusivity and commercial returns in competitive biotech markets.
Exposure
Accounting
Judgemental itemsThe avexitide acquisition created a large charge because the asset had no alternative future use at acquisition.
Impact: Can materially increase operating losses in the period of acquisition
Clinical trial and CMO costs are estimated before invoices are finalized, so accruals can move reported expenses.
Impact: Affects quarterly R&D expense and liabilities
The RELYVRIO/ALBRIOZA discontinuation led to inventory impairment and losses on firm purchase commitments.
Impact: Can create large one-time cost of sales or operating expense charges
A clinical-stage company typically uses equity awards heavily to retain talent, affecting operating expenses.
Impact: Raises reported SG&A and R&D expense without immediate cash outflow
Similar listed companies
Publicly listed companies with a comparable business focus.
Alumis Inc
ALMS · Pharmaceutical Preparations
Neurocrine Biosciences, Inc
NBIX · Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders.
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Last updated: 24/09/2026